Literature DB >> 9398689

The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia.

R Girgis1, J S Winter.   

Abstract

Even with current so called physiologic doses of glucocorticoid replacement therapy, children with congenital adrenal hyperplasia (CAH) often show relative short stature and delayed bone maturation, an observation that suggests possible long-term effects on bone metabolism of daily transient post-absorptive hypercortisolemia. In 28 patients with 21-hydroxylase or 17 alpha-hydroxylase deficiency (16 females and 12 males, ages 4.9-22 yr) who had received oral cortisol 10-15 mg/M2/day for 4.7-22 yr, we studied cortisol bioavailability, growth, bone maturation, vertebral bone mineral density, and various markers of bone formation and resorption. Patients were grouped according to mean on-therapy serum 170H-progesterone or progesterone levels as tight control (170HP < 10 nmol/L), fair control (170HP 10-40 nmol/L or progesterone 1.0-1.5 nmol/L), or poor control (170HP > 40 nmol/L). There was no difference in peak post-absorptive serum cortisol or area under the concentration-time curve, and only three patients had a peak serum cortisol of more than 700 nmol/L. There was no difference in present height Z-score (-0.96; -0.24; -0.6), height Z-score at age 2 yr (-1.5; +0.4; -1.3), or current growth velocity Z-score (-0.1; +1.2; -2.2) between the groups, but bone maturation Z-score was significantly delayed (-1.63) in the tight control group and advanced (+0.8) in the poor control group. Present height was highly correlated (r = 0.8) with height at age 2 yr. Serum calcium, phosphorus, alkaline phosphatase, parathormone, and 25OH-vitamin D levels were all normal. There was no difference between the groups in age-corrected vertebral bone mineral density, and no difference in serum osteocalcin, procollagen peptide, or collagen C-terminal telopeptide, nor in urinary amino-terminal telopeptide. The data suggest that current methods of cortisol replacement do not significantly influence bone formation, resorption or density during childhood and therefore should not contribute to adult osteoporosis. The possibility remains that hypercortisolemia during infancy produces the short stature and delayed bone maturation that are present by the age 2 yr.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9398689     DOI: 10.1210/jcem.82.12.4320

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

Review 1.  Growth in congenital adrenal hyperplasia.

Authors:  An Tt Nguyen; Justin J Brown; Garry L Warne
Journal:  Indian J Pediatr       Date:  2006-01       Impact factor: 1.967

Review 2.  Congenital adrenal hyperplasia: an update in children.

Authors:  Christine M Trapp; Phyllis W Speiser; Sharon E Oberfield
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2011-06       Impact factor: 3.243

3.  Bone mineral density and body composition in children with congenital adrenal hyperplasia.

Authors:  Alyssa Halper; Belen Sanchez; James S Hodges; Aaron S Kelly; Donald Dengel; Brandon M Nathan; Anna Petryk; Kyriakie Sarafoglou
Journal:  Clin Endocrinol (Oxf)       Date:  2018-03-24       Impact factor: 3.478

4.  Final adult height in children with congenital adrenal hyperplasia treated with growth hormone.

Authors:  Karen Lin-Su; Madeleine D Harbison; Oksana Lekarev; Maria G Vogiatzi; Maria I New
Journal:  J Clin Endocrinol Metab       Date:  2011-03-30       Impact factor: 5.958

5.  An Evidence-Based Model of Multidisciplinary Care for Patients and Families Affected by Classical Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.

Authors:  Traci L Schaeffer; Jeanie B Tryggestad; Ashwini Mallappa; Adam E Hanna; Sowmya Krishnan; Steven D Chernausek; Laura J Chalmers; William G Reiner; Brad P Kropp; Amy B Wisniewski
Journal:  Int J Pediatr Endocrinol       Date:  2010-03-18

6.  Alternative strategies for the treatment of classical congenital adrenal hyperplasia: pitfalls and promises.

Authors:  Karen J Loechner; James T McLaughlin; Ali S Calikoglu
Journal:  Int J Pediatr Endocrinol       Date:  2010-06-24

7.  Bone health should be an important concern in the care of patients affected by 21 hydroxylase deficiency.

Authors:  Anne Bachelot; Zeina Chakhtoura; Dinane Samara-Boustani; Jérome Dulon; Philippe Touraine; Michel Polak
Journal:  Int J Pediatr Endocrinol       Date:  2010-09-28

Review 8.  [Testicular adrenal rest tumors (TART) in adult men with classic congenital adrenal hyperplasia (CAH)].

Authors:  P Knape; N Reisch; H-G Dörr; M Reincke; S Lenk; M Quinkler
Journal:  Urologe A       Date:  2008-12       Impact factor: 0.639

9.  Correlation of Bone Mineral Parameters with Anthropometric Measurements and the Effect of Glucocorticoids on Bone Mineral Parameters in Congenital Adrenal Hyperplasia.

Authors:  Ramaswamy Ganesh; Natarajan Suresh; Lalitha Janakiraman; Karnam Ravikumar
Journal:  Indian J Pediatr       Date:  2015-07-31       Impact factor: 1.967

10.  Bone mineral status in children with congenital adrenal hyperplasia.

Authors:  Amy Fleischman; Julie Ringelheim; Henry A Feldman; Catherine M Gordon
Journal:  J Pediatr Endocrinol Metab       Date:  2007-02       Impact factor: 1.634

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.